Instrument Inactif

Communiqués Celsion Corporation Nasdaq

Actions

US15117N3052

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

24/06	Imunon, Inc. Annonce le verrouillage de la base de données pour l'étude de phase 2 OVATION 2 avec IMNN-001 dans le cancer de l'ovaire avancé	CI
05/06	IMUNON, Inc. annonce les premiers participants vaccinés dans le cadre de l'essai clinique de phase 1 IMNN-101	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer	24/06	AQ
First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial	05/06	AQ
Imunon : Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting entitled “A Phase II Study Evaluating the effect of IMNN-001 on Second Look Laparoscopy (SLL) when Administered in Combination with Bevacizumab (BEV) and Neoadjuvant Chemother	03/06	PU
Imunon : Management Change/Compensation - Form 8-K	20/05	PU
Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting	15/05	AQ
IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study	13/05	AQ
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update	13/05	AQ
IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO	08/05	AQ
IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024	06/05	AQ
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101	18/04	AQ
IMUNON Reports Compliance with Nasdaq Listing Requirements	11/04	AQ
IMUNON Reports 2023 Financial Results and Provides Business Update	28/03	AQ
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses	25/03	AQ
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024	21/03	AQ
IMUNON Files IND Application to Begin Human Testing of IMNN-101	13/03	AQ
IMUNON Announces Leadership Change	12/03	AQ
Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5	29/02	AQ
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer	27/02	AQ
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine	22/02	AQ
IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	11/12	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Celsion Corporation Nasdaq

Actions

US15117N3052

Communiqués

Filtres